Practical Insights in Novel Immune Therapies in Multiple Myeloma Workshop
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!
This high-impact educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Preliminary Agenda
Our sponsors:
Practical Insights in Novel Immune Therapies in Multiple Myeloma Workshop
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!
This high-impact educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Preliminary Agenda
Our sponsors:
Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – East Coast
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!
This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Preliminary Agenda
Our sponsors:
Future of Drug Development in Multiple Myeloma: An IMS-FDA Joint Symposium
The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. However, relapses are common and multiple myeloma remains a difficult disease to treat, so the need for new therapies remains. Recent trial results and developments in the field of multiple myeloma necessitate a discussion of the current paradigm to facilitate future drug development and improve patient outcomes.
On November 8-9, 2022, the IMS will host a joint symposium with the FDA, to provide a forum for open discussion among academia, industry and regulatory agencies about clinical drug development in multiple myeloma. This workshop will discuss trial design, patient population, and endpoints in the different multiple myeloma disease settings with an aim to advance the future of drug development. Ultimately, this meeting serves to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population.
Preliminary Program
Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!
This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Preliminary Agenda
Our sponsors:
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
